SLC5A2 and Hyperinsulinemia: In summary, these data demonstrate that strategies to mitigate hyperinsulinemia—preferably both fasting and postprandial hyperinsulinemia, as can be accomplished using SGLT2 inhibitors, which are already in the clinic, or insulin sensitizers under development—may be therapeutic targets worthy of further exploration to attenuate breast and/or colon cancer risk and progression.